{
    "organizations": [],
    "uuid": "d5b0dfd04290ca46eadab777afe4f0dfa9cb7a6a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inovio-opens-trial-to-test-its-vgx/brief-inovio-opens-trial-to-test-its-vgx-3100-drug-in-hpv-patients-idUSASC0A312",
    "ord_in_thread": 0,
    "title": "BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Inovio Pharmaceuticals Inc:\n* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV â€“ THE NO. 1 SEXUALLY TRANSMITTED DISEASE\n* INOVIO PHARMACEUTICALS INC - STUDY IS PLANNING TO ENROLL APPROXIMATELY 24 PATIENTS AND WILL ADMINISTER AT LEAST THREE DOSES OF VGX-3100 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T20:13:00.000+03:00",
    "crawled": "2018-05-22T19:28:14.024+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "inovio",
        "pharmaceutical",
        "inc",
        "inovio",
        "open",
        "phase",
        "trial",
        "third",
        "indication",
        "treat",
        "hpv",
        "sexually",
        "transmitted",
        "disease",
        "inovio",
        "pharmaceutical",
        "inc",
        "study",
        "planning",
        "enroll",
        "approximately",
        "patient",
        "administer",
        "least",
        "three",
        "dos",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}